Paulus Kirchhof

197.1k total citations · 16 hit papers
554 papers, 26.1k citations indexed

About

Paulus Kirchhof is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Paulus Kirchhof has authored 554 papers receiving a total of 26.1k indexed citations (citations by other indexed papers that have themselves been cited), including 487 papers in Cardiology and Cardiovascular Medicine, 65 papers in Molecular Biology and 58 papers in Surgery. Recurrent topics in Paulus Kirchhof's work include Atrial Fibrillation Management and Outcomes (314 papers), Cardiac Arrhythmias and Treatments (256 papers) and Cardiac electrophysiology and arrhythmias (204 papers). Paulus Kirchhof is often cited by papers focused on Atrial Fibrillation Management and Outcomes (314 papers), Cardiac Arrhythmias and Treatments (256 papers) and Cardiac electrophysiology and arrhythmias (204 papers). Paulus Kirchhof collaborates with scholars based in Germany, United Kingdom and Italy. Paulus Kirchhof's co-authors include A. John Camm, Gerhard Hindricks, Larissa Fabritz, Ulrich Schotten, Gregory Y.H. Lip, Andreas Goette, Hein Heidbüchel, Jonas Oldgren, Karl‐Heinz Kück and Martin Borggrefe and has published in prestigious journals such as The Lancet, JAMA and Journal of Biological Chemistry.

In The Last Decade

Paulus Kirchhof

513 papers receiving 25.4k citations

Hit Papers

2015 ESC Guidelines for the management of patients with v... 2011 2026 2016 2021 2015 2016 2015 2011 2015 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
    2015 2.5k citations A. John Camm, Gerhard Hindricks et al. European Heart Journal profile →
  2. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS
    2016 1.5k citations Paulus Kirchhof, Hans‐Christoph Diener et al. profile →
  3. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
    2015 1.3k citations A. John Camm, Gerhard Hindricks et al. EP Europace profile →
  4. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal
    2011 891 citations Paulus Kirchhof et al. profile →
  5. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
    2015 745 citations Hein Heidbüchel, Peter Verhamme et al. EP Europace profile →
  6. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
    2013 570 citations Hein Heidbüchel, Peter Verhamme et al. EP Europace profile →
  7. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases
    2020 563 citations Paulus Kirchhof, Stefan Blankenberg et al. profile →
  8. 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
    2012 553 citations A. John Camm, Gregory Y.H. Lip et al. profile →
  9. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
    2014 363 citations Gregory Y.H. Lip, Paulus Kirchhof et al. profile →
  10. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
    2015 331 citations A. John Camm, Pierre Amarenco et al. European Heart Journal profile →
  11. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
    2015 306 citations A. John Camm, Gerhard Hindricks et al. profile →
  12. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure
    2021 141 citations Andreas Rillig, Günter Breithardt et al. Circulation profile →
  13. The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation
    2022 113 citations A. John Camm, Paulus Kirchhof et al. profile →
  14. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study
    2022 101 citations Holger Reinecke, Christiane Engelbertz et al. Circulation profile →
  15. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
    2023 100 citations Nina Becher, Jeff S. Healey et al. Circulation profile →
  16. Atrial fibrillation burden: a new outcome predictor and therapeutic target
    2024 39 citations Nina Becher, Andreas Metzner et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paulus Kirchhof Germany 75 23.0k 3.3k 3.2k 2.3k 2.0k 554 26.1k
Günter Breithardt Germany 73 22.9k 1.0× 3.3k 1.0× 5.1k 1.6× 2.0k 0.9× 2.4k 1.2× 415 25.3k
Katherine T. Murray United States 38 15.8k 0.7× 2.1k 0.6× 2.7k 0.8× 1.3k 0.6× 1.9k 0.9× 108 19.5k
Stefan H. Hohnloser Germany 90 29.4k 1.3× 2.0k 0.6× 4.0k 1.2× 3.1k 1.4× 2.1k 1.0× 422 31.9k
Patrick T. Ellinor United States 82 26.7k 1.2× 7.3k 2.2× 3.0k 0.9× 3.1k 1.3× 3.0k 1.5× 364 36.5k
Cynthia M. Tracy United States 49 20.8k 0.9× 1.4k 0.4× 2.9k 0.9× 2.2k 0.9× 1.9k 0.9× 105 22.7k
William G. Stevenson United States 80 32.6k 1.4× 1.6k 0.5× 2.1k 0.7× 3.2k 1.4× 2.0k 1.0× 471 35.8k
Joseph C. Cleveland United States 48 15.7k 0.7× 1.3k 0.4× 2.6k 0.8× 3.6k 1.6× 2.1k 1.0× 207 20.1k
Harry J.G.M. Crijns Netherlands 93 36.3k 1.6× 3.5k 1.0× 4.2k 1.3× 3.4k 1.4× 3.1k 1.5× 605 42.4k
Craig T. January United States 57 20.8k 0.9× 7.2k 2.2× 2.9k 0.9× 1.2k 0.5× 1.6k 0.8× 137 23.4k
L. Kristin Newby United States 75 18.6k 0.8× 2.2k 0.7× 1.7k 0.5× 6.3k 2.7× 1.7k 0.8× 339 26.4k

Countries citing papers authored by Paulus Kirchhof

Since Specialization
Citations

This map shows the geographic impact of Paulus Kirchhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paulus Kirchhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paulus Kirchhof more than expected).

Fields of papers citing papers by Paulus Kirchhof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paulus Kirchhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paulus Kirchhof. The network helps show where Paulus Kirchhof may publish in the future.

Co-authorship network of co-authors of Paulus Kirchhof

This figure shows the co-authorship network connecting the top 25 collaborators of Paulus Kirchhof. A scholar is included among the top collaborators of Paulus Kirchhof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paulus Kirchhof. Paulus Kirchhof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caterina, Raffaele De, Martin Unverdorben, Eue‐Keun Choi, et al.. (2025). Two‐Year Follow‐Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA‐AF Program. Clinical Cardiology. 48(3). e70091–e70091.
2.
3.
Choi, Jong‐Il, Songsak Kiatchoosakun, Hung‐Fat Tse, et al.. (2024). Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia　― One-Year Data From the Global ETNA-AF Program ―. Circulation Reports. 6(3). 86–93. 1 indexed citations
4.
Becher, Peter Moritz, Felix Lindberg, Lina Benson, et al.. (2024). Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure. ESC Heart Failure. 12(2). 900–911. 2 indexed citations
5.
Rottner, Laura, Katrin Borof, Ilaria My, et al.. (2023). A novel saline-based occlusion tool allows for dye-less cryoballoon-based pulmonary vein isolation and fluoroscopy reduction. Frontiers in Cardiovascular Medicine. 10. 1156500–1156500. 2 indexed citations
6.
Dettling, Angela, Jessica Weimann, Jonas Sundermeyer, et al.. (2023). Association of systemic inflammation with shock severity, 30-day mortality, and therapy response in patients with cardiogenic shock. Clinical Research in Cardiology. 113(2). 324–335. 6 indexed citations
7.
Chao, Tze‐Fan, Martin Unverdorben, Paulus Kirchhof, et al.. (2023). Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program. Journal of Clinical Medicine. 12(5). 1870–1870. 5 indexed citations
8.
Reinecke, Holger, Christiane Engelbertz, Rupert Bauersachs, et al.. (2022). A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 147(4). 296–309. 101 indexed citations breakdown →
9.
Boriani, Giuseppe, et al.. (2021). Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. Journal of Clinical Medicine. 10(13). 2879–2879. 6 indexed citations
10.
Becher, Peter Moritz, Benedikt Schrage, Alina Goßling, et al.. (2021). Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. Critical Care. 25(1). 325–325. 2 indexed citations
11.
Reyat, Jasmeet S., Winnie Chua, Victor Roth Cardoso, et al.. (2020). Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. JCI Insight. 5(16). 50 indexed citations
12.
Knecht, Stefan, et al.. (2019). Second look Holter ECG in neurorehabilitation. SHILAP Revista de lepidopterología. 1(1). 41–41. 2 indexed citations
13.
Herm, Juliane, Johannes Schurig, Martin Martinek, et al.. (2019). MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies. BMC Cardiovascular Disorders. 19(1). 58–58. 7 indexed citations
14.
Verma, Atul, Andrew C.T. Ha, Paulus Kirchhof, et al.. (2017). The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial. American Heart Journal. 197. 124–132. 42 indexed citations
15.
Heidbüchel, Hein, Peter Verhamme, Marco Alings, et al.. (2016). Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal. 38(27). ehw058–ehw058. 188 indexed citations
16.
Heidbüchel, Hein, Peter Verhamme, Marco Alings, et al.. (2015). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. EP Europace. 17(10). 1467–1507. 745 indexed citations breakdown →
17.
Hæusler, Karl Georg, Paulus Kirchhof, Peter U. Heuschmann, et al.. (2015). Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. American Heart Journal. 172. 19–25. 21 indexed citations
18.
Camm, A. John, Pierre Amarenco, Sylvia Haas, et al.. (2014). XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vascular Health and Risk Management. 10. 425–425. 29 indexed citations
19.
Schlitt, Axel, Andrea Rubboli, J. Valencia, et al.. (2011). Abstract 12001: AFCAS, a Prospective Multicenter Registry of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting: Comparison of Chads2- with Cha2ds2-vasc Score. Circulation. 124. 1 indexed citations
20.
Haverkamp, Wilhelm, Richard Ammer, Paulus Kirchhof, et al.. (2002). Vorhofflimmern: Molekularbiologische Grundlagen. Herz. 27(4). 301–305. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Günter Breithardt Breakdown of academic impact, for papers by Katherine T. Murray Breakdown of academic impact, for papers by Stefan H. Hohnloser Breakdown of academic impact, for papers by Patrick T. Ellinor Breakdown of academic impact, for papers by Cynthia M. Tracy Breakdown of academic impact, for papers by William G. Stevenson Breakdown of academic impact, for papers by Joseph C. Cleveland Breakdown of academic impact, for papers by Harry J.G.M. Crijns Breakdown of academic impact, for papers by Craig T. January Breakdown of academic impact, for papers by L. Kristin Newby
Rankless by CCL
2026